Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Fig. 1

Multiple myeloma responses at 3 months follow-up. A First response assessment performed at a median of 12 (10–35) days after ide-cel infusion; B 3 months follow-up response. For response assessment, the IMWG criteria have been used, and MRD negativity was assessed by multiparameter flow cytometry. Abbreviations: CR: complete response; MR: minimal response; ORR: objective response rate; PD: progressive disease; PR: partial response; sCR: stringent complete response; VGPR: very good partial response

Back to article page